204 related articles for article (PubMed ID: 31613176)
21. Functional studies of new GLA gene mutations leading to conformational Fabry disease.
Filoni C; Caciotti A; Carraresi L; Cavicchi C; Parini R; Antuzzi D; Zampetti A; Feriozzi S; Poisetti P; Garman SC; Guerrini R; Zammarchi E; Donati MA; Morrone A
Biochim Biophys Acta; 2010 Feb; 1802(2):247-52. PubMed ID: 19941952
[TBL] [Abstract][Full Text] [Related]
22. Translational readthrough at
Testa MF; Lombardi S; Bernardi F; Ferrarese M; Belvini D; Radossi P; Castaman G; Pinotti M; Branchini A
Haematologica; 2023 Feb; 108(2):472-482. PubMed ID: 35924581
[TBL] [Abstract][Full Text] [Related]
23. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
Germain DP; Poenaru L
Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
[TBL] [Abstract][Full Text] [Related]
24. Clinical and genetic investigation of a Japanese family with cardiac fabry disease. Identification of a novel α-galactosidase A missense mutation (G195V).
Nakagawa N; Maruyama H; Ishihara T; Seino U; Kawabe J; Takahashi F; Kobayashi M; Yamauchi A; Sasaki Y; Sakamoto N; Ota H; Tanabe Y; Takeuchi T; Takenaka T; Kikuchi K; Hasebe N
Int Heart J; 2011; 52(5):308-11. PubMed ID: 22008442
[TBL] [Abstract][Full Text] [Related]
25. The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators.
Chen J; Thrasher K; Fu L; Wang W; Aghamohammadzadeh S; Wen H; Tang L; Keeling KM; Falk Libby E; Bedwell DM; Rowe SM
Am J Physiol Lung Cell Mol Physiol; 2023 Jun; 324(6):L756-L770. PubMed ID: 37014818
[TBL] [Abstract][Full Text] [Related]
26. A nonsense mutation (R220X) in the alpha-galactosidase A gene causes typical Fabry disease in both genders.
Maki N; Komatsuda A; Wakui H; Oyama Y; Kodama T; Ohtani H; Kigawa A; Aiba N; Imai H; Motegi M; Yamaguchi A; Sawada K
Clin Nephrol; 2004 Mar; 61(3):185-90. PubMed ID: 15077869
[TBL] [Abstract][Full Text] [Related]
27. Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease.
Yang CC; Lai LW; Whitehair O; Hwu WL; Chiang SC; Lien YH
Clin Genet; 2003 Mar; 63(3):205-9. PubMed ID: 12694230
[TBL] [Abstract][Full Text] [Related]
28. Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease.
Chien YH
Hum Genet; 2009 Apr; 125(3):336. PubMed ID: 19309800
[No Abstract] [Full Text] [Related]
29. Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).
Ebrahim HY; Baker RJ; Mehta AB; Hughes DA
J Inherit Metab Dis; 2012 Mar; 35(2):325-34. PubMed ID: 21972175
[TBL] [Abstract][Full Text] [Related]
30. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.
Schäfer E; Baron K; Widmer U; Deegan P; Neumann HP; Sunder-Plassmann G; Johansson JO; Whybra C; Ries M; Pastores GM; Mehta A; Beck M; Gal A
Hum Mutat; 2005 Apr; 25(4):412. PubMed ID: 15776423
[TBL] [Abstract][Full Text] [Related]
31. Factors Affecting Readthrough of Natural Versus Premature Termination Codons.
Beryozkin A; Nagel-Wolfum K; Banin E; Sharon D
Adv Exp Med Biol; 2023; 1415():149-155. PubMed ID: 37440028
[TBL] [Abstract][Full Text] [Related]
32. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
[TBL] [Abstract][Full Text] [Related]
33. Identification of four novel mutations in five unrelated Korean families with Fabry disease.
Lee JK; Kim GH; Kim JS; Kim KK; Lee MC; Yoo HW
Clin Genet; 2000 Sep; 58(3):228-33. PubMed ID: 11076046
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
[TBL] [Abstract][Full Text] [Related]
35. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of the GLA gene in Mexican families with Fabry disease.
Gutiérrez-Amavizca BE; Gal A; Ortíz-Orozco R; Orth U; Prado Montes De Oca E; Gutiérrez-Amavizca JP; Figuera LE
J Genet; 2017 Mar; 96(1):161-164. PubMed ID: 28360401
[TBL] [Abstract][Full Text] [Related]
37. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
38. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
39. A missense mutation of the α-galactosidase A gene in a Chinese family of Fabry disease with renal failure.
Wang C; Wang Y; Zhu F; Xiong J
Kidney Blood Press Res; 2013; 37(4-5):221-8. PubMed ID: 23867994
[TBL] [Abstract][Full Text] [Related]
40. Functional Restoration of
Abreu RBV; Gomes TT; Nepomuceno TC; Li X; Fuchshuber-Moraes M; De Gregoriis G; Suarez-Kurtz G; Monteiro ANA; Carvalho MA
Front Pharmacol; 2022; 13():935995. PubMed ID: 35837282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
